You are here

Article Text

Article menu
Download PDFPDF
Prevalence
Cross-sectional
Severe adverse reactions are rare with infusions of infliximab in a community setting
  1. Yusuf Yazici
  1. New York University School of Medicine, NYU Hospital for Joint Diseases, New York, USA
  1. Correspondence to Yusuf Yazici
    246 East 20th Street, New York, NY 10003, USA; yusuf.yazici{at}nyumc.org

https://doi.org/10.1136/ebn1002

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Commentary on: Ducharme J, Pelletier C, Zacharias R. The safety of infliximab infusions in the community setting. Can J Gastroenterol 2010;24:307–11.OpenUrlPubMedWeb of Science

    In this study, Ducharme and colleagues report on the experience in community infusion centres with patients using infliximab for a variety of indications. As the authors state, randomised clinical trials are not the ideal environment to assess safety,1 ,2 and ‘real-world’ experience after the drugs are available to use give us a more complete picture for both the efficacy and the safety of any medication. This is a commendable effort that will provide important information for practitioners and patients alike.

    In this retrospective chart review study, all infusions …

    View Full Text

    Footnotes

    • Competing interests YY has been a consultant or speaker for BMS, Celgene, Centocor, Genentech, Merck, Pfizer, Roche and UCB.